Sun, Jun 29, 2025 page3

• Better Alzheimer’s diagnostic tools needed: experts

  • Staff writer, with CNA
  • • 
    • 
    • 

  As Taiwan begins administering two newly approved drugs for early-stage Alzheimer’s disease, more accurate diagnostic tools are needed to identify suitable patients and guide treatment decisions, medical experts said.

  Kisunla, developed by US pharmaceutical company Eli Lilly, and Leqembi, jointly developed by Eisai in Japan, Biogen in the US and BioArctic in Sweden, were approved by the Food and Drug Administration (FDA) earlier this year for use.

  The US Food and Drug Administration approved Kisunla last year and Leqembi in 2023.

  

  A nurse holds up a vial of new Alzheimer’s drug Kisunla at Far Eastern Memorial Hospital in New Taipei City on Monday.

  Photo: CNA

  Some patients in Taiwan began receiving the two drugs last week, but are doing so at their own expense, because the drugs are not covered by the National Health Insurance system.

  A standard 18-month course for each of the two drugs costs about NT$1.5 million (US$51,405).

  Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, Kaohsiung Chang Gung Memorial Hospital Department of Neurology deputy director Chang Chiung-chih (張瓊之) said.

  To accurately identify the disease, doctors often need to spend a lot of time communicating with a new patient’s family and asking about the patient’s daily functioning, including asking whether they can still shop for groceries or perform basic calculations by themselves, Chang said.

  With the two newly approved drugs for early-stage Alzheimer’s beginning to be administered across Taiwan, more accurate diagnostic tools are needed to identify patients in the early stages who are suitable for treatment, she said.

  Researchers believe that Alzheimer’s disease is caused by the combined accumulation of amyloid and tau protein in the brain, and that the presence of tau protein is closely linked to the onset of symptoms — the broader the tau spread, the more severe the cognitive decline, she said.

  Chang said that based on the correlation between tau protein deposition and the onset of Alzheimer’s, she hoped that in the future medical imaging for tau protein would enable earlier detection and help predict disease progression.

  Current diagnostic methods for Alzheimer’s rely on assessment scales and clinical guidelines to determine whether a person “very likely” has the disease, Taiwan Dementia Society president Hsu Jung-lung (徐榮隆) said.

  Biomarkers are critical to confirming an Alzheimer’s diagnosis, and such indicators could help determine whether a patient is eligible for the new treatments that might slow the disease’s progression, he said.

  Jang Ming-kuei (張明奎), founder of transnational biotech company Aprinoia, said a tau protein imaging agent developed by the company can visualize tau protein accumulation in the brain, but the agent is still undergoing clinical trials.

  The company is in discussions with the FDA regarding its drug approval application, including the submission of safety and efficacy data, Jang said.

  An estimated 350,000 people in Taiwan have some form of dementia, with 60 to 70 percent of them having Alzheimer’s. About half, or fewer than 100,000 patients, might qualify for the new treatments, said Yan Sui-hing (甄瑞興), director of Far Eastern Memorial Hospital’s dementia center.
• Most Popular

  • 1

    Investors diversify from TSMC to other winners of AI boom

  • 2

    HSR malfunction causes delays, reduced service

  • 3

    Japan ‘mystery illness’ not new: CDC

  • 4

    Taiwan eyes 100,000 drones a month

  • 5

    Taiwan, China coast guards argue in South China Sea